A Better Way to Detect Off-Target Genome Changes From Base Editors

Why It Matters

Accurate, cost‑effective off‑target profiling accelerates regulatory approval and de‑riskes therapeutic genome editing, boosting investor confidence and patient access.

Key Takeaways

• CHANGE-seq-BE detects off‑targets with 95% on‑target specificity
• Uses only ~5% sequencing reads versus conventional methods
• Works for both adenine and cytosine base editors
• Enables rapid FDA safety data for genome‑editing therapies
• Adopted in clinical trials and patient‑specific treatments

Pulse Analysis

Base editors have emerged as a precise alternative to nuclease‑based CRISPR, swapping single DNA letters without creating double‑strand breaks. Yet the therapeutic promise of these tools hinges on rigorous safety profiling, because even a single off‑target deamination can trigger unintended disease pathways. Traditional off‑target screens either blanket the genome with costly whole‑genome sequencing or rely on pre‑selected sites that miss unexpected edits. The industry therefore faces a trade‑off between comprehensive coverage and practical resource constraints.

The St. Jude team answered that trade‑off with CHANGE‑seq‑BE, a circular‑DNA‑based assay that tags edited loci for selective sequencing. After fragmenting genomic DNA into nanocircles, the base editor is applied in vitro; a specialized enzyme linearizes only circles that have undergone base conversion, allowing those fragments to be enriched and sequenced. The workflow captures virtually all adenine and cytosine editor activities while consuming roughly five percent of the reads required by conventional whole‑genome approaches. In head‑to‑head benchmarks, CHANGE‑seq‑BE reproduced every off‑target identified by existing methods and uncovered dozens of novel sites, demonstrating superior sensitivity.

Because safety data can accelerate regulatory review, the assay has already been leveraged in an emergency FDA filing for a base‑editor therapy targeting X‑linked Hyper IgM syndrome, confirming 95.4 % on‑target specificity and no measurable off‑targets. Clinical programs at St. Jude and other institutions are now integrating CHANGE‑seq‑BE into pre‑clinical pipelines to prioritize editors with the highest therapeutic index. As more companies move toward patient‑specific in‑vivo editing, the method’s low cost and rapid turnaround are likely to become a de‑facto standard, shaping the next wave of genome‑editing therapeutics.